Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Interferon α-2b maintenance in multiple myeloma
NCT00732641Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2000
- Primary completion
- Nov 2010
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
A Phase 3 trial of peginterferon alfa-2b in multiple myeloma (MM), sponsored by Merck & Co.. Started Dec 2000; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00732641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00732641.